INTC vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Intel Corporation and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-25.
Intel Corporation · Technology
$82.54
-5.4% upside to fair value
Grade D
VS
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(+10.8%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
JNJ |
| Current Price |
$82.54 |
$230.69 |
| Fair Value Estimate |
$78.09 |
$255.61 |
| Upside to Fair Value |
-5.4%
|
+10.8%
|
| Market Cap |
$414.4B |
$555.9B |
| Forward P/E |
-132.2x
|
26.8x
|
| EV / EBITDA |
50.1x
|
18.5x
|
| Price / Sales |
7.7x
|
5.8x
|
| Price / FCF |
-132.9x
|
28.2x
|
| Revenue Growth YoY |
+7.2%
|
+9.9%
|
| Gross Margin |
35.4%
|
69.1%
|
| Operating Margin |
-9.4%
|
26.9%
|
| Return on Equity |
-3.0%
|
26.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
3.54%
|
| Analyst Consensus |
Hold
|
Buy
|
Investment Thesis
Intel Corporation is a leading semiconductor company transitioning to a foundry business model while maintaining significant revenue from client computing and data center segments. Despite a strong market position and experienced leadership, the company faces earnings pressure with a 354% decline in earnings in the most recent quarter and negative margins. The stock trades at $82.54, which is 5.4…
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
INTC |
JNJ |
| Zone Low |
$58.57 |
$191.71 |
| Zone High |
$66.38 |
$217.27 |
| In Buy Zone? |
No
|
No
|